Relationship Between COPD Progression and Frailty Progression: A Five-year Observation in Real Clinical Practice.

IF 2.7 3区 医学 Q2 RESPIRATORY SYSTEM
Koichi Nishimura, Masaaki Kusunose, Ayumi Shibayama, Kazuhito Nakayasu
{"title":"Relationship Between COPD Progression and Frailty Progression: A Five-year Observation in Real Clinical Practice.","authors":"Koichi Nishimura, Masaaki Kusunose, Ayumi Shibayama, Kazuhito Nakayasu","doi":"10.2147/COPD.S512326","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Although a cross-sectional association between frailty and chronic obstructive pulmonary disease (COPD) has been established, the longitudinal relationship between the progression of both frailty and COPD remains unclear.</p><p><strong>Materials and methods: </strong>This longitudinal study followed 87 COPD patients over five years, with evaluations conducted every six months. Participants underwent pulmonary function tests and completed the Kihon Checklist, a tool widely used in Japan to assess frailty. Kihon Checklist scores range from 0 (no frailty) to 25 (severe frailty), categorizing participants as robust (0-3), pre-frail (4-7), or frail (8-25). Annual changes were analyzed using linear mixed models.</p><p><strong>Results: </strong>A significant association was observed between time and worsening frailty classification, with patients transitioning from robust to pre-frail or from pre-frail to frail (odds ratio: 1.224, <i>p</i> = 0.004). However, the GOLD stages (GOLD 1 to GOLD 4) did not exhibit significant progression over five years. The cohort demonstrated significant declines in forced expiratory volume in one second (FEV<sub>1</sub>) and increases in Kihon Checklist total scores. FEV<sub>1</sub> decreased by an estimated mean of 28.6 mL per year (95% CI: 18.9-38.4, p < 0.001), while the Kihon Checklist total score increased by 0.30 annually (95% CI: 0.09-0.51, p = 0.006). Estimated FEV<sub>1</sub> declined significantly from baseline after two years in the baseline frail group (p < 0.01), after 3.5 years in the pre-frail group (p < 0.01), and after four years in the robust group (p < 0.05). Although the GOLD 3+4 group showed a significant increase in Kihon Checklist total scores after 3.5 years (p < 0.05), no significant change was observed in the GOLD 1 and GOLD 2 groups.</p><p><strong>Conclusion: </strong>COPD patients with frailty show a more rapid decline in FEV<sub>1</sub>, indicating accelerated COPD progression. These findings suggest frailty is static and only COPD is progressing.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"1955-1964"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12176056/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S512326","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Although a cross-sectional association between frailty and chronic obstructive pulmonary disease (COPD) has been established, the longitudinal relationship between the progression of both frailty and COPD remains unclear.

Materials and methods: This longitudinal study followed 87 COPD patients over five years, with evaluations conducted every six months. Participants underwent pulmonary function tests and completed the Kihon Checklist, a tool widely used in Japan to assess frailty. Kihon Checklist scores range from 0 (no frailty) to 25 (severe frailty), categorizing participants as robust (0-3), pre-frail (4-7), or frail (8-25). Annual changes were analyzed using linear mixed models.

Results: A significant association was observed between time and worsening frailty classification, with patients transitioning from robust to pre-frail or from pre-frail to frail (odds ratio: 1.224, p = 0.004). However, the GOLD stages (GOLD 1 to GOLD 4) did not exhibit significant progression over five years. The cohort demonstrated significant declines in forced expiratory volume in one second (FEV1) and increases in Kihon Checklist total scores. FEV1 decreased by an estimated mean of 28.6 mL per year (95% CI: 18.9-38.4, p < 0.001), while the Kihon Checklist total score increased by 0.30 annually (95% CI: 0.09-0.51, p = 0.006). Estimated FEV1 declined significantly from baseline after two years in the baseline frail group (p < 0.01), after 3.5 years in the pre-frail group (p < 0.01), and after four years in the robust group (p < 0.05). Although the GOLD 3+4 group showed a significant increase in Kihon Checklist total scores after 3.5 years (p < 0.05), no significant change was observed in the GOLD 1 and GOLD 2 groups.

Conclusion: COPD patients with frailty show a more rapid decline in FEV1, indicating accelerated COPD progression. These findings suggest frailty is static and only COPD is progressing.

慢性阻塞性肺病进展与衰弱进展的关系:真实临床实践的5年观察
目的:虽然衰弱与慢性阻塞性肺疾病(COPD)之间的横断面关联已经建立,但衰弱与COPD进展之间的纵向关系仍不清楚。材料和方法:这项纵向研究随访了87例COPD患者5年,每6个月进行一次评估。参与者进行了肺功能测试,并完成了Kihon检查表,这是一种在日本广泛使用的评估虚弱程度的工具。Kihon检查表得分范围从0(无虚弱)到25(严重虚弱),将参与者分为健壮(0-3),预虚弱(4-7)或虚弱(8-25)。采用线性混合模型分析年变化。结果:观察到时间与恶化的虚弱分类之间存在显著关联,患者从健壮过渡到虚弱前期或从虚弱前期过渡到虚弱(优势比:1.224,p = 0.004)。然而,GOLD阶段(GOLD 1至GOLD 4)在五年内没有明显的进展。该队列显示一秒钟用力呼气量(FEV1)显著下降,Kihon检查表总分增加。FEV1估计平均每年减少28.6 mL (95% CI: 18.9-38.4, p < 0.001),而Kihon Checklist总分每年增加0.30 (95% CI: 0.09-0.51, p = 0.006)。基线虚弱组2年后估测FEV1较基线显著下降(p < 0.01),虚弱前组3.5年后(p < 0.01),强健组4年后(p < 0.05)。虽然GOLD 3+4组在3.5年后Kihon Checklist总分显著增加(p < 0.05),但GOLD 1和GOLD 2组无显著变化。结论:虚弱的COPD患者FEV1下降更快,提示COPD进展加快。这些发现表明虚弱是静态的,只有COPD在进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
10.70%
发文量
372
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信